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Background: Many centers choose endovascular intervention as their ﬁrst-line treatment for crural occlusions in patients
with critical limb ischemia (Rutherford 4-6). However, unsuccessful interventions often result in major amputation.
Therefore, pedal bypass surgery should be considered as an alternative ﬁrst-line treatment. We reviewed the impact of a
prior endovascular intervention on the outcome of our patients’ pedal bypass procedures.
Methods: A retrospective analysis was conducted for all patients who had undergone pedal bypass surgery in our
department from February 2008 to October 2012. We performed 75 pedal bypass operations in 71 patients (male, 54;
female, 17; median age, 72 years; range, 29-90 years). In 36 of those cases, patients had undergone a prior infrapopliteal
endovascular intervention (PEI group). In 39 cases, patients underwent bypass surgery as ﬁrst-line treatment because
their prior angiography had resulted in either unsuccessful endovascular intervention, or intervention had been deemed
‘not feasible’ (BSF group). Only autologous vein grafts were used, and no retrograde intervention was done via the pedal
arteries. Endpoints of the analysis were primary and secondary patency rates, mortality, and limb salvage at 1 year
postoperatively.
Results: Overall primary patency at 1 year was 58.3%, and secondary patency was 61.3%. Limb salvage was 76.8% and
survival was 80.4%. Graft occlusion within 30 days was 18.7%. Revision in those cases was futile and 78.6% of patients had
to undergo major amputation. Primary patency at 1 year was 67.0% in PEI group vs 48.3% in BSF group (P[ .409) and
secondary patency was 73.5% vs 48.6% (P [ .100). Prior endovascular intervention had no signiﬁcant impact on either
limb salvage (82.3% vs 71.6% at 1 year; P[ .515) or graft occlusions within 30 days (19.4% vs 17.9%; P[ .547). Survival
rate at 1 year was 79.5% in PEI group and 81.3% in BSF group (P [ .765). Risk factors and indications were similar in
both groups.
Conclusions: Crural endovascular intervention does not seem to have a negative impact on the outcome of subsequent
pedal bypass surgery. Requirements are avoiding a destruction of the target vessel and opting for timely bypass surgery
whenever endovascular treatment does not achieve a sufﬁcient perfusion for wounds to heal. Early graft occlusions are
associated with a higher risk for major amputation. (J Vasc Surg 2014;59:1583-7.)An aging population, unhealthy lifestyles, and diseases
of afﬂuence, such as diabetes, all are risk factors for periph-
eral arterial occlusive disease. Every 20 seconds, somewhere
in the world, a leg is lost to diabetes.1,2 Atherosclerotic le-
sions frequently involve the crural vessels, and the preva-
lence of long and multilevel lesions is high.3 This process
is known as critical limb ischemia (CLI), and patients
frequently present with rest pain, ulcers, and gangrene
(Rutherford 4-6). Their substantial comorbidities put
them at risk for complications related to open bypass sur-
gery, and morbidity and mortality rates are high. At the
same time endovascular treatment (ET) techniques have
improved tremendously. Therefore, many centers have
adopted an endovascular-ﬁrst strategy. However, the
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://dx.doi.org/10.1016/j.jvs.2013.11.071(BASIL) trial showed that patients who had undergone
bypass surgery after a previously unsuccessful ET demon-
strated worse amputation-free survival rates than those
who had undergone primary surgical treatment without
prior ET.4-6 Various studies present good patency rates
for pedal bypasses.7-10 However, they all lack sufﬁcient in-
formation on whether the underlying ﬁrst-line treatment
was surgery or endovascular intervention. The purpose of
this study was to evaluate the outcome of pedal bypass op-
erations in a center where ET is the ﬁrst-line treatment. We
assessed the impact of a prior crural angioplasty on the
outcome of pedal bypass surgery in patients with CLI.
Then we compared their outcome with the outcome of pa-
tients who underwent bypass surgery as their primary
treatment.
METHODS
This is a retrospective analysis of 75 pedal bypasses
between February 2008 and October 2012. During this
time, we did 326 cural endovascular interventions as ﬁrst-
line treatment for occlusions. The indication was CLI
with rest pain, ulcers, or gangrene (Rutherford 4-6). After
an initial postinterventional improvement, 36 cases (prior
endovascular intervention [PEI group]) went on to
require pedal bypass surgery (with a median of 3 months
after the intervention) due to increasing necroses. Their1583
Table I. Endovascular procedures
All Stenosis
Long
segment
occlusion
Percutaneous
transluminal
angioplasty/
atherectomy
Distal popliteal artery
(below knee)
5 2 3 4/1
Tibial-ﬁbular trunk 5 3 2 5/0
Anterior tibial artery 12 1 11 12/0
Posterior tibial artery 7 1 6 7/0
Peroneal artery 11 2 9 11/0
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shown in Table I. In 39 cases, patients underwent pedal
bypass surgery ﬁrst as their primary treatment without prior
successful endovascular intervention (BSF group). We
compared primary and secondary patency, limb salvage
rates, and survival between the groups. Primary patency
was deﬁned as the period between bypass surgery and ﬁrst
occlusion of the bypass. Secondary patency was deﬁned as
the period between bypass surgery and second occlusion of
the bypass.
A limb was deemed salvageable if perfusion could be
improved. Necrosis and ulcer of toes and heels were
deemed salvageable, as well as multiple locations of necrosis
on the foot. Gangrene of the entire foot was deemed not
salvageable. Three patients underwent minor amputation
before receiving any kind of revascularization treatment
because there appeared to be sufﬁcient perfusion for the
amputation wounds to heal. However, this turned out
not to be the case, and all three patients (PEI group,
n ¼ 1; BSF group, n ¼ 2) had to undergo subsequent
treatment for revascularization (with a median of 2 weeks
after the minor amputation). Four patients in the PEI
group underwent minor amputation after their endovascu-
lar revascularization but before their bypass operation. In
40% of all patients (PEI group, 47.2%; BSF group,
33.3%; P ¼ .161), planned minor amputations were per-
formed in concert with their bypass operations. The demo-
graphics, risk factors, and indications are shown in Table II,
and the bypass characteristics are shown in Table III. There
was no retrograde intervention via the pedal arteries. Only
autologous vein grafts were used, and all bypasses were
controlled by angiography to exclude any technical failure.
Postoperatively, 74% of patients were managed with statins,
and all of patients were put on anticoagulant medication. All
received the vitamin K antagonist Phenprocoumon for their
anticoagulation therapy. Postoperative graft surveillance
follow-ups (at discharge, and at 6, 12, 24, and 36 months
postoperation) included pulse examination and duplex ultra-
sound imaging. Patients whose last duplex scan had been
more than 6 months ago were called in for another follow-
up in January 2013 to compile the most up-to-date data.
Follow-up was complete with no patients lost during the
period of our study. Wound healing and pulsatile bypass
perfusion were evaluated. The bypass was considered
occluded when no duplex signal could be detected.Statistical analysis was done using SPSS 15 (SPSS Inc,
Chicago, Ill). Kaplan-Meier life table method evaluated
graft patency, limb salvage, and patient survival. Nonpara-
metric Mantel-Cox log-rank test was used to compare the
survival curves between the groups. The variables subjected
to nonparametric testing were survival, primary patency,
secondary patency, and limb salvage. c2 test and Fisher
exact test were used to compare patients’ risk factors, indi-
cations, bypass characteristics, and morbidity and mortality
between the PEI group and BSF group. P < .05 was
deemed statistically signiﬁcant.
RESULTS
Morbidity and mortality rates. Comparative
morbidity and mortality information is shown in
Table IV. The overall 30-day mortality was 4.0% (PEI
group, 2.8%; BSF group, 5.1%; P ¼ .525). There were no
procedure-related deaths (one myocardial infarction, one
renal failure, one pulmonary failure). There were no sig-
niﬁcant differences in major complications between both
groups. The overall survival rate was 80.4% at 1 year (PEI
group, 79.5%; BSF group, 81.3%; P ¼ .765; Fig 1).
Graft patency and limb salvage rates. Overall pri-
mary patency at 1 year was 58.3% (PEI group, 67.0%;
BSF group, 48.3%; P ¼ .409; Fig 2). Overall 1-year sec-
ondary patency was 61.3%, without reaching statistical
signiﬁcance (PEI group, 73.5%; BSF group, 48.6%; P ¼
.100; Fig 3). There was a cumulative of 14 graft occlusions
within the ﬁrst 30 postoperative days (18.7%). Again, there
was no signiﬁcant difference between the groups (PEI
group, 19.4%; BSF group, 17.9%; P ¼ .551).
Limb salvage at 1 year (Fig 4) was 82.3% in PEI group
and 71.6% in BSF group (P ¼ .515) with an overall limb
salvage of 76.8%. Out of the 14 patients with early graft
occlusions, 78.6% underwent major amputation. We did
not attempt any further ETs in any of the patients with
early graft occlusions before major amputation. A total of
11.1% of patients in the PEI group and 7.7% of patients
in the BSF group underwent minor amputation at some
point after their bypass surgery (P ¼ .454).
Secondary interventions and operations. We per-
formed ﬁve graft thrombectomies in ﬁve of the 14 patients
with early graft occlusions. Unfortunately, none of them
were successful, and four of them had to undergo major
amputation. Furthermore, ﬁve patients successfully under-
went ET for graft stenosis. One acute graft occlusion was
successfully treated with lytic therapy. Lytic therapy failed
in two other patients. Out of the successfully treated pa-
tients, three went on to require another intervention.
Two of them received ET, and one underwent thrombec-
tomy surgery. All of those interventions were successful.
DISCUSSION
The purpose of this study was to assess whether an
endovascular-ﬁrst approach to crural occlusions has a nega-
tive impact on the outcome of subsequent pedal bypass
surgery. Our study shows that a prior endovascular inter-
vention does not affect the outcome of pedal bypass
Table II. Patient demographics and indications
All (n ¼ 75) PEI group (n ¼ 36) BSF group (n ¼ 39) P
Median age (range), years 72 (29-90) 71.5 (39-90) 71.5 (59-81)
Male 56 (74.6) 26 (72.2) 30 (76.9) .420
Diabetes mellitus 58 (77.3) 28 (77.8) 30 (76.9) .575
Coronary artery disease 32 (42.7) 15 (41.7) 17 (43.6) .562
Hypertension 71 (94.7) 33 (91.7) 38 (97.4) .278
Renal failure 35 (46.7) 17 (47.2) 18 (46.2) .555
Smoker/ex-smoker 11 (14.7) 6 (16.7) 5 (12.8) .442
Rest pain 5 (6.7) 1 (2.8) 4 (10.3) .205
Ulcer/gangrene 70 (93.3) 35 (97.2) 35 (89.7) .195
BSF, Bypass surgery ﬁrst; PEI, prior endovascular intervention.
Data presented as number (%) unless otherwise indicated.
Table III. Bypass characteristics
All (n ¼ 75), No. (%) PEI group (n ¼ 36), No. (%) BSF group (n ¼ 39), No. (%) P
Level of inﬂow
Distal superﬁcial femoral 5 (6.7) 1 (2.8) 4 (10.35) .205
Above-knee popliteal 4 (5.3) 2 (5.6) 2 (5.1) .662
Below-knee popliteal 52 (69.3) 26 (72.2) 26 (66.7) .220
Anterior tibial 11 (14.7) 6 (16.7) 5 (12.8) .442
Posterior tibial 3 (4.0) 1 (2.8) 2 (5.1) .201
Level of outﬂow
Dorsalis pedis 56 (74.7) 26 (72.2) 30 (76.9) .420
Posterior tibial 9 (12.0) 6 (16.7) 3 (7.7) .227
Plantar arterial arch 10 (13.3) 4 (11.1) 6 (15.4) .421
BSF, Bypass surgery ﬁrst; PEI, prior endovascular intervention.
Table IV. Morbidity and mortality
All (n ¼ 75), No. (%) PEI group (n ¼ 36), No. (%) BSF group (n ¼ 39), No. (%) P
30-day mortality 3 (4.0) 1 (2.8) 2 (5.1) .525
Myocardial infarction 1 (1.3) 1 (2.8) 0 .168
Renal failure 1 (1.3) 0 1 (2.6) .267
Pulmonary failure 1 (1.3) 0 1 (2.6) .267
30-day graft failure 14 (18.7) 7 (19.4) 7 (17.9) .551
30-day major amputation 12 (16.0) 6 (16.7) 6 (15.4) .564
Minor amputation 7 (9.3) 4 (11.1) 3 (7.7) .454
BSF, Bypass surgery ﬁrst; PEI, prior endovascular intervention.
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any sort could not be detected. The data demonstrated no
signiﬁcant difference in primary and secondary patency,
limb salvage, or survival. This is where our results differ
from the results of other studies. So far, the BASIL trial
is the only randomized trial that compared the outcomes
of bypass surgery with and without prior endovascular ther-
apy. In the BASIL trial, amputation-free survival at 1 year
was 40% for post-angioplasty bypass surgery vs 70% for pri-
mary bypass surgery.5 Nolan et al described a signiﬁcantly
different 1-year amputation-free survival for patients with
postangioplasty bypass surgery and patients with primary
bypass surgery (53% vs 76%; P ¼ .03).6 One explanation
for this could be an impaired runoff caused by complica-
tions of endovascular intervention, such as embolizationor thrombosis.11 Prior studies by Joels et al indicate that
endovascular interventions alter the location and level of
the future bypass.11 However, when we analyzed prior
angiographies, we could not detect such altered levels of
in-ﬂow or a changed distal target vessel that was caused
by prior ET. There are three possible explanations for
our results. First, our study only includes prior crural endo-
vascular interventions. So we only compared the outcomes
of pedal bypass surgeries with and without prior ET below
the knee. Prior endovascular interventions that involved
the superﬁcial artery were not included. Second, we did
not perform any retrograde endovascular interventions via
the pedal arteries. We are conﬁdent that therefore the
risk of embolization or thrombosis in the pedal runoff ves-
sels was reduced to a minimum. Third, we opted for timely
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Fig 1. Survival rate for prior endovascular intervention (PEI)
group and bypass surgery ﬁrst (BSF) group. SE, Standard error.
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Fig 2. Primary patency for prior endovascular intervention (PEI)
group and bypass surgery ﬁrst (BSF) group. SE, Standard error.
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Fig 4. Limb salvage for prior endovascular intervention (PEI)
group and bypass surgery ﬁrst (BSF) group. SE, Standard error.
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Fig 3. Secondary patency for prior endovascular intervention (PEI)
group and bypass surgery ﬁrst (BSF) group. SE, Standard error.
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perfusion. This strategy minimized the time that tissue
was exposed to insufﬁcient perfusion.
Medical literature puts the average primary patency
at 1 year somewhere between 60% and 80% and the secondary
patency somewhere between 67% and 87%.7-10,12 However,
there is no information on whether endovascular intervention
or bypass surgery was the underlying ﬁrst-line treatment.Interestingly, patency rates are lower in more recent studies
than in older ones.7,9,10,13,14 A possible explanation for this
trend is the increase of ETs in the last years. Successful endo-
vascular intervention often makes pedal bypass surgery redun-
dant. Our study demonstrates an overall primary patency of
58.3% at 1 year and a secondary patency of 61.3%. To our
knowledge, this is the ﬁrst paper that presents data for pedal
bypasses in the context of an endovascular-ﬁrst strategy.
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Volume 59, Number 6 Uhl et al 1587Medical literature reports the 30-day graft failure rate
to be between 4.2% and 11%.7-9 Panneton et al describe
a 30-day graft failure of 19% in a subgroup analysis of
nondiabetic patients.13 Our study yields a failure rate of
18.7% (n ¼ 14). A possible explanation for this relatively
high failure rate is that we always tried a bypass procedure
before major amputation. Five of those patients underwent
bypass thrombectomy, which unfortunately turned out to
be unsuccessful. We identiﬁed a bad runoff to be the reason
for these early occlusions. All bypasses were controlled by
angiography. Therefore, we were able to exclude technical
failure. These results show that any reoperation for early
graft failure has to be considered carefully and its indication
has to be conﬁrmed properly.
This study also has its limitations. It remains unclear
how a retrograde intervention via the pedal arteries would
have inﬂuenced the outcome. Moreover, the monitoring
time was limited, and the cohort was small. Nevertheless
our study is able to give some guidance on how to best
treat patients with CLI. It answers a previously unacknowl-
edged question on the impact of an endovascular-ﬁrst
strategy.
CONCLUSIONS
An endovascular-ﬁrst approach to crural occlusions
does not seem to affect the outcome of subsequent pedal
bypass surgery. Therefore, endovascular-ﬁrst strategy seems
to be justiﬁed in this special type of CLI. We were also able
to show that early graft occlusions are associated with a
higher risk for major amputation.
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